ArticleCancer science2025

KEYNOTE-A17: First-Line Pembrolizumab Plus Cisplatin-Pemetrexed in Japanese Participants With Advanced Pleural Mesothelioma.

Takashi Kijima et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.